IE Biotechnology & Medical Research

Alkermes Plc (ALKS)

Track

Over the last 90 days, Alkermes Plc has seen significant insider selling, with a net value of -$687,007. Notable transactions include multiple planned and proposed sales by executives like Craig C. Hopkinson and David Joseph Gaffin. The company's stock has performed strongly, up 58.6% in 90 days, reaching near its 52-week high.
Ticker: ALKS Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Alkermes Plc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Gaffin David Joseph
EVP, CLO, Alkermes, Inc.
2 sales — total 200,000 USD
Planned sale 6 Jul 2026
Value US$1,982,447.42 | Price 262.72 | Shares 35,632
Proposed sale 6 Jul 2026
Value US$1,169,776.51 | Price 275.18 | Shares 99,732
Planned sale 1 Jul 2026
Value US$4,600,814.13 | Price 50.32 | Shares 12,309
Planned sale 1 Jul 2026
Value US$3,780,241.70 | Price 372.37 | Shares 42,852
Proposed sale 1 Jul 2026
Value US$100,000.00 | Price 51.51 | Shares 1,000
Planned sale 12 Jun 2026
Value US$90,200.00 | Price 45.10 | Shares 2,000
Proposed sale 12 Jun 2026
Value US$90,200.00 | Price 45.10 | Shares 2,000
Planned sale 4 Jun 2026
Value US$87,563.70 | Price 43.05 | Shares 2,034
Planned sale 4 Jun 2026
Value US$87,563.70 | Price 43.05 | Shares 2,034
Proposed sale 4 Jun 2026
Value US$87,563.70 | Price 43.05 | Shares 2,034
Planned sale 1 Jun 2026
Value US$375,043.50 | Price 41.67 | Shares 9,000
Proposed sale 1 Jun 2026
Value US$375,043.23 | Price 41.67 | Shares 9,000
Proposed sale 1 Jun 2026
Value US$375,043.23 | Price 41.67 | Shares 9,000
Sale 29 May 2026
Value US$687,007.26 | Price 42.36 | Shares 16,217
Planned sale 4 May 2026
Value US$67,528.80 | Price 33.20 | Shares 2,034
Proposed sale 4 May 2026
Value US$67,528.80 | Price 33.20 | Shares 2,034
Planned sale 1 May 2026
Value US$300,559.50 | Price 33.40 | Shares 9,000
Proposed sale 1 May 2026
Value US$300,559.55 | Price 33.40 | Shares 9,000
Planned sale 6 Apr 2026
Value US$70,315.38 | Price 34.57 | Shares 2,034
Proposed sale 6 Apr 2026
Value US$70,315.38 | Price 34.57 | Shares 2,034
Planned sale 1 Apr 2026
Value US$319,604.40 | Price 35.51 | Shares 9,000
Proposed sale 1 Apr 2026
Value US$319,604.00 | Price 35.51 | Shares 9,000
Planned sale 3 Mar 2026
Value US$60,531.84 | Price 29.76 | Shares 2,034
Proposed sale 3 Mar 2026
Value US$60,531.84 | Price 29.76 | Shares 2,034
Planned sale 2 Mar 2026
Value US$201,808.10 | Price 29.29 | Shares 6,890
Planned sale 2 Mar 2026
Value US$180,000.00 | Price 30.00 | Shares 6,000
Proposed sale 2 Mar 2026
Value US$180,000.00 | Price 30.00 | Shares 6,000
Planned sale 2 Mar 2026
Value US$59,575.86 | Price 29.29 | Shares 2,034
Proposed sale 2 Mar 2026
Value US$59,575.86 | Price 29.29 | Shares 2,034
Planned sale 2 Mar 2026
Value US$267,485.40 | Price 29.72 | Shares 9,000
Proposed sale 2 Mar 2026
Value US$267,485.14 | Price 29.72 | Shares 9,000
Proposed sale 2 Feb 2026
Value US$2,115,674.45 | Price 34.57 | Shares 61,200
Planned sale 2 Feb 2026
Value US$1,116,877.29 | Price 34.78 | Shares 32,113
Planned sale 2 Feb 2026
Value US$998,795.22 | Price 34.34 | Shares 29,087
Proposed sale 2 Feb 2026
Value US$305,384.28 | Price 33.93 | Shares 9,000
Planned sale 2 Feb 2026
Value US$134,160.00 | Price 33.54 | Shares 4,000
Planned sale 2 Feb 2026
Value US$171,224.50 | Price 34.24 | Shares 5,000
Proposed sale 8 Jan 2026
Value US$150,004.95 | Price 30.00 | Shares 5,000
Planned sale 8 Jan 2026
Value US$150,005.00 | Price 30.00 | Shares 5,000
Proposed sale 2 Jan 2026
Value US$112,000.00 | Price 28.00 | Shares 4,000
Planned sale 2 Jan 2026
Value US$112,000.00 | Price 28.00 | Shares 4,000
Planned sale 3 Dec 2025
Value US$112,447.12 | Price 30.00 | Shares 3,748
Proposed sale 3 Dec 2025
Value US$112,447.26 | Price 30.00 | Shares 3,748
Proposed sale 1 Dec 2025
Value US$117,200.00 | Price 29.30 | Shares 4,000
Planned sale 1 Dec 2025
Value US$117,200.00 | Price 29.30 | Shares 4,000
Proposed sale 3 Nov 2025
Value US$273,441.50 | Price 30.38 | Shares 9,000
Planned sale 3 Nov 2025
Value US$273,441.60 | Price 30.38 | Shares 9,000
Proposed sale 15 Oct 2025
Value US$283,776.70 | Price 31.53 | Shares 9,000
Planned sale 15 Oct 2025
Value US$283,776.30 | Price 31.53 | Shares 9,000
Proposed sale 10 Jun 2025
Value US$103,654.06 | Price 31.09 | Shares 3,334
Planned sale 10 Jun 2025
Value US$103,654.06 | Price 31.09 | Shares 3,334
Planned sale 9 Jun 2025
Value US$106,489.35 | Price 31.95 | Shares 3,333
Proposed sale 9 Jun 2025
Value US$106,489.35 | Price 31.95 | Shares 3,333
Planned sale 28 Feb 2025
Value US$65,892.00 | Price 34.00 | Shares 1,938
Planned sale 25 Feb 2025
Value US$131,978.18 | Price 35.26 | Shares 3,743
Planned sale 20 Feb 2025
Value US$47,360.63 | Price 35.69 | Shares 1,327
Planned sale 13 Feb 2025
Value US$3,920,001.41 | Price 36.02 | Shares 108,833
Planned sale 13 Feb 2025
Value US$1,210,696.22 | Price 34.02 | Shares 35,586
Proposed sale 13 Feb 2025
Value US$5,130,694.15 | Price 35.53 | Shares 144,419
Planned sale 12 Feb 2025
Value US$1,101,470.05 | Price 33.27 | Shares 33,108
Planned sale 12 Feb 2025
Value US$5,616,807.51 | Price 32.69 | Shares 171,813
Proposed sale 12 Feb 2025
Value US$6,718,276.17 | Price 32.78 | Shares 204,921
Planned sale 30 Jan 2025
Value US$3,234,381.53 | Price 32.05 | Shares 100,918
Proposed sale 30 Jan 2025
Value US$3,234,380.13 | Price 32.05 | Shares 100,918
Proposed sale 9 Dec 2024
Value US$85,708.35 | Price 31.85 | Shares 2,691
Planned sale 9 Dec 2024
Value US$85,708.35 | Price 31.85 | Shares 2,691
Proposed sale 9 Dec 2024
Value US$1,961,403.62 | Price 32.07 | Shares 61,151
Planned sale 9 Dec 2024
Value US$1,961,406.09 | Price 32.07 | Shares 61,151
Proposed sale 5 Dec 2024
Value US$290,461.50 | Price 31.50 | Shares 9,221
Planned sale 5 Dec 2024
Value US$290,461.50 | Price 31.50 | Shares 9,221
Proposed sale 4 Dec 2024
Value US$441,550.16 | Price 30.77 | Shares 14,349
Planned sale 4 Dec 2024
Value US$441,550.30 | Price 30.77 | Shares 14,349
Proposed sale 27 Nov 2024
Value US$151,813.20 | Price 29.15 | Shares 5,208
Planned sale 27 Nov 2024
Value US$151,813.20 | Price 29.15 | Shares 5,208
Proposed sale 11 Nov 2024
Value US$1,774,578.08 | Price 30.08 | Shares 58,996
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-07-06 2026-07-06 PlS Planned sale
Gaffin David Joseph

EVP, CLO, Alkermes, Inc.

Officer
35,632 +26.0%
262.72
US$1,982,447 		35,632 +26.0% 262.72 US$1,982,447
2026-07-06 2026-07-06 PrS Proposed sale
Gaffin David Joseph

Officer

Officer
99,732
275.18
US$1,169,777 		99,732 275.18 US$1,169,777
2026-07-01 2026-07-01 PlS Planned sale
Hopkinson Craig C.

EVP R&D, Chief Medical Officer

Officer
12,309 -32.1%
50.32
US$4,600,814 		12,309 -32.1% 50.32 US$4,600,814
2026-07-01 2026-07-01 PlS Planned sale
Hopkinson Craig C.

EVP R&D, Chief Medical Officer

Officer
1,000 -10.1%
51.46
US$100,000 		1,000 -10.1% 51.46 US$100,000
2026-07-01 2026-07-01 PrS Proposed sale
Hopkinson Craig C.

Officer

Officer
1,000
51.51
US$100,000 		1,000 51.51 US$100,000
2026-06-12 2026-06-12 PlS Planned sale
Wright Christopher I
Non-Executive Director
2,000 -7.2%
45.10
US$90,200 		2,000 -7.2% 45.10 US$90,200
2026-06-12 2026-06-12 PrS Proposed sale
Wright Christopher I

Officer

Officer
2,000
45.10
US$90,200 		2,000 45.10 US$90,200
2026-06-04 2026-06-04 PlS Planned sale
Gaffin David Joseph

EVP, CLO, Alkermes, Inc.

Officer
2,034 -0.9%
43.05
US$87,564 		2,034 -0.9% 43.05 US$87,564
2026-06-04 2026-06-04 PlS Planned sale
Gaffin David Joseph

EVP, CLO, Alkermes, Inc.

Officer
2,034 -0.9%
43.05
US$87,564 		2,034 -0.9% 43.05 US$87,564
2026-06-04 2026-06-04 PrS Proposed sale
Gaffin David Joseph

Officer

Officer
2,034
43.05
US$87,564 		2,034 43.05 US$87,564
2026-06-01 2026-06-01 PlS Planned sale
Hopkinson Craig C.

EVP R&D, Chief Medical Officer

Officer
9,000 -10.4%
41.67
US$375,044 		9,000 -10.4% 41.67 US$375,044
2026-06-01 2026-06-01 PrS Proposed sale
Hopkinson Craig C.

Officer

Officer
9,000
41.67
US$375,043 		9,000 41.67 US$375,043
2026-06-01 2026-06-01 PrS Proposed sale
Hopkinson Craig C.

Officer

Officer
9,000
41.67
US$375,043 		9,000 41.67 US$375,043
2026-05-29 2026-05-29 S Sale
2.5
Parisi Samuel Joseph

VP, Finance (Interim PAO)

Officer
16,217 -67.8%
42.36
US$687,007 		16,217 -67.8% 42.36 US$687,007
2026-05-04 2026-05-04 PlS Planned sale
Gaffin David Joseph

EVP, CLO, Alkermes, Inc.

Officer
2,034 -0.9%
33.20
US$67,529 		2,034 -0.9% 33.20 US$67,529
2026-05-04 2026-05-04 PrS Proposed sale
Gaffin David Joseph

Officer

Officer
2,034
33.20
US$67,529 		2,034 33.20 US$67,529
2026-05-01 2026-05-01 PlS Planned sale
Hopkinson Craig C.

EVP R&D, Chief Medical Officer

Officer
9,000 -10.0%
33.40
US$300,560 		9,000 -10.0% 33.40 US$300,560
2026-05-01 2026-05-01 PrS Proposed sale
Hopkinson Craig C.

Officer

Officer
9,000
33.40
US$300,560 		9,000 33.40 US$300,560
2026-04-06 2026-04-06 PlS Planned sale
Gaffin David Joseph

EVP, CLO, Alkermes, Inc.

Officer
2,034 -0.9%
34.57
US$70,315 		2,034 -0.9% 34.57 US$70,315
2026-04-06 2026-04-06 PrS Proposed sale
Gaffin David Joseph

Officer

Officer
2,034
34.57
US$70,315 		2,034 34.57 US$70,315
2026-04-01 2026-04-01 PlS Planned sale
Hopkinson Craig C.

EVP R&D, Chief Medical Officer

Officer
9,000 -9.5%
35.51
US$319,604 		9,000 -9.5% 35.51 US$319,604
2026-04-01 2026-04-01 PrS Proposed sale
Hopkinson Craig C.

Officer

Officer
9,000
35.51
US$319,604 		9,000 35.51 US$319,604
2026-03-04 2026-03-03 PlS Planned sale
Gaffin David Joseph

EVP, CLO, Alkermes, Inc.

Officer
2,034 -0.9%
29.76
US$60,532 		2,034 -0.9% 29.76 US$60,532
2026-03-03 2026-03-03 PrS Proposed sale
Gaffin David Joseph

Officer

Officer
2,034
29.76
US$60,532 		2,034 29.76 US$60,532
2026-03-04 2026-03-02 PlS Planned sale
2.5
Parisi Samuel Joseph

VP, Finance (Interim PAO)

Officer
6,890 -47.2%
29.29
US$201,808 		6,890 -47.2% 29.29 US$201,808
2026-03-04 2026-03-02 PlS Planned sale
Nichols Christian Todd

SVP, Chief Commercial Officer

Officer
6,000 -5.2%
30.00
US$180,000 		6,000 -5.2% 30.00 US$180,000
2026-03-04 2026-03-02 PlS Planned sale
Gaffin David Joseph

EVP, CLO, Alkermes, Inc.

Officer
2,034 -0.8%
29.29
US$59,576 		2,034 -0.8% 29.29 US$59,576
2026-03-04 2026-03-02 PlS Planned sale
Hopkinson Craig C.

EVP R&D, Chief Medical Officer

Officer
9,000 -9.1%
29.72
US$267,485 		9,000 -9.1% 29.72 US$267,485
2026-03-02 2026-03-02 PrS Proposed sale
Nichols Christian Todd

Officer

Officer
6,000
30.00
US$180,000 		6,000 30.00 US$180,000
2026-03-02 2026-03-02 PrS Proposed sale
Gaffin David Joseph

Officer

Officer
2,034
29.29
US$59,576 		2,034 29.29 US$59,576
2026-03-02 2026-03-02 PrS Proposed sale
Hopkinson Craig C.

Officer

Officer
9,000
29.72
US$267,485 		9,000 29.72 US$267,485
2026-02-02 2026-02-02 PrS Proposed sale
3.3
Cooke Shane

Officer

Officer
61,200
34.57
US$2,115,674 		61,200 34.57 US$2,115,674
2026-02-02 2026-02-02 PrS Proposed sale
Hopkinson Craig C.

Officer

Officer
9,000
33.93
US$305,384 		9,000 33.93 US$305,384
2026-02-02 2026-02-02 PlS Planned sale
Hopkinson Craig C.

EVP R&D, Chief Medical Officer

Officer
4,000 -6.5%
33.54
US$134,160 		4,000 -6.5% 33.54 US$134,160
2026-02-02 2026-02-02 PlS Planned sale
Hopkinson Craig C.

EVP R&D, Chief Medical Officer

Officer
5,000 -7.5%
34.24
US$171,224 		5,000 -7.5% 34.24 US$171,224
2026-02-02 2026-02-02 PlS Planned sale
3.3
Cooke Shane
Non-Executive Director
32,113 -23.6%
34.78
US$1,116,877 		32,113 -23.6% 34.78 US$1,116,877
2026-02-02 2026-02-02 PlS Planned sale
3.3
Cooke Shane
Non-Executive Director
29,087 -17.6%
34.34
US$998,795 		29,087 -17.6% 34.34 US$998,795
2026-01-08 2026-01-08 PrS Proposed sale
Hopkinson Craig C.

Officer

Officer
5,000
30.00
US$150,005 		5,000 30.00 US$150,005
2026-01-08 2026-01-08 PlS Planned sale
Hopkinson Craig C.

EVP R&D, Chief Medical Officer

Officer
5,000 -7.5%
30.00
US$150,005 		5,000 -7.5% 30.00 US$150,005
2026-01-02 2026-01-02 PrS Proposed sale
Hopkinson Craig C.

Officer

Officer
4,000
28.00
US$112,000 		4,000 28.00 US$112,000
2026-01-02 2026-01-02 PlS Planned sale
Hopkinson Craig C.

EVP R&D, Chief Medical Officer

Officer
4,000 -6.1%
28.00
US$112,000 		4,000 -6.1% 28.00 US$112,000
2025-12-05 2025-12-03 PlS Planned sale
Hopkinson Craig C.

EVP R&D, Chief Medical Officer

Officer
3,748 -5.4%
30.00
US$112,447 		3,748 -5.4% 30.00 US$112,447
2025-12-03 2025-12-03 PrS Proposed sale
Hopkinson Craig C.

Officer

Officer
3,748
30.00
US$112,447 		3,748 30.00 US$112,447
2025-12-01 2025-12-01 PrS Proposed sale
Hopkinson Craig C.

Officer

Officer
4,000
29.30
US$117,200 		4,000 29.30 US$117,200
2025-12-01 2025-12-01 PlS Planned sale
Hopkinson Craig C.

EVP R&D, Chief Medical Officer

Officer
4,000 -5.7%
29.30
US$117,200 		4,000 -5.7% 29.30 US$117,200
2025-11-03 2025-11-03 PrS Proposed sale
Hopkinson Craig C.

Officer

Officer
9,000
30.38
US$273,442 		9,000 30.38 US$273,442
2025-11-03 2025-11-03 PlS Planned sale
Hopkinson Craig C.

EVP R&D, Chief Medical Officer

Officer
9,000 -11.4%
30.38
US$273,442 		9,000 -11.4% 30.38 US$273,442
2025-10-15 2025-10-15 PrS Proposed sale
Hopkinson Craig C.

Officer

Officer
9,000
31.53
US$283,777 		9,000 31.53 US$283,777
2025-10-15 2025-10-15 PlS Planned sale
Hopkinson Craig C.

EVP R&D, Chief Medical Officer

Officer
9,000 -10.9%
31.53
US$283,776 		9,000 -10.9% 31.53 US$283,776
2025-06-10 2025-06-10 PrS Proposed sale
Nichols Christian Todd

Officer

Officer
3,334
31.09
US$103,654 		3,334 31.09 US$103,654
2025-06-10 2025-06-10 PlS Planned sale
Nichols Christian Todd

SVP, Chief Commercial Officer

Officer
3,334 -3.7%
31.09
US$103,654 		3,334 -3.7% 31.09 US$103,654
2025-06-10 2025-06-09 PlS Planned sale
Nichols Christian Todd

SVP, Chief Commercial Officer

Officer
3,333 -3.6%
31.95
US$106,489 		3,333 -3.6% 31.95 US$106,489
2025-06-09 2025-06-09 PrS Proposed sale
Nichols Christian Todd

Officer

Officer
3,333
31.95
US$106,489 		3,333 31.95 US$106,489
2025-02-28 2025-02-28 PlS Planned sale
2.5
Parisi Samuel Joseph

VP, Finance (Interim PAO)

Officer
1,938 -20.1%
34.00
US$65,892 		1,938 -20.1% 34.00 US$65,892
2025-02-25 2025-02-25 PlS Planned sale
2.5
Parisi Samuel Joseph

VP, Finance (Interim PAO)

Officer
3,743 -32.7%
35.26
US$131,978 		3,743 -32.7% 35.26 US$131,978
2025-02-20 2025-02-20 PlS Planned sale
2.5
Parisi Samuel Joseph

VP, Finance (Interim PAO)

Officer
1,327 -14.7%
35.69
US$47,361 		1,327 -14.7% 35.69 US$47,361
2025-02-14 2025-02-13 PlS Planned sale
Hopkinson Craig C.

EVP R&D, Chief Medical Officer

Officer
108,833 -65.3%
36.02
US$3,920,001 		108,833 -65.3% 36.02 US$3,920,001
2025-02-14 2025-02-13 PlS Planned sale
Hopkinson Craig C.

EVP R&D, Chief Medical Officer

Officer
35,586 -17.6%
34.02
US$1,210,696 		35,586 -17.6% 34.02 US$1,210,696
2025-02-13 2025-02-13 PrS Proposed sale
Hopkinson Craig C.

Officer

Officer
144,419
35.53
US$5,130,694 		144,419 35.53 US$5,130,694
2025-02-14 2025-02-12 PlS Planned sale
Hopkinson Craig C.

EVP R&D, Chief Medical Officer

Officer
33,108 -36.4%
33.27
US$1,101,470 		33,108 -36.4% 33.27 US$1,101,470
2025-02-14 2025-02-12 PlS Planned sale
Hopkinson Craig C.

EVP R&D, Chief Medical Officer

Officer
171,813 -65.4%
32.69
US$5,616,808 		171,813 -65.4% 32.69 US$5,616,808
2025-02-12 2025-02-12 PrS Proposed sale
Hopkinson Craig C.

Officer

Officer
204,921
32.78
US$6,718,276 		204,921 32.78 US$6,718,276
2025-01-31 2025-01-30 PlS Planned sale
Hopkinson Craig C.

EVP R&D, Chief Medical Officer

Officer
100,918 -69.5%
32.05
US$3,234,382 		100,918 -69.5% 32.05 US$3,234,382
2025-01-30 2025-01-30 PrS Proposed sale
Hopkinson Craig C.

Officer

Officer
100,918
32.05
US$3,234,380 		100,918 32.05 US$3,234,380
2024-12-09 2024-12-09 PrS Proposed sale
LAURENCIN CATO T

Director

Non-Executive Director
2,691
31.85
US$85,708 		2,691 31.85 US$85,708
2024-12-09 2024-12-09 PrS Proposed sale
Hopkinson Craig C.

Officer

Officer
61,151
32.07
US$1,961,404 		61,151 32.07 US$1,961,404
2024-12-09 2024-12-09 PlS Planned sale
LAURENCIN CATO T
Non-Executive Director
2,691 -10.5%
31.85
US$85,708 		2,691 -10.5% 31.85 US$85,708
2024-12-09 2024-12-09 PlS Planned sale
Hopkinson Craig C.

EVP R&D, Chief Medical Officer

Officer
61,151 -56.2%
32.07
US$1,961,406 		61,151 -56.2% 32.07 US$1,961,406
2024-12-05 2024-12-05 PrS Proposed sale
Hopkinson Craig C.

Officer

Officer
9,221
31.50
US$290,462 		9,221 31.50 US$290,462
2024-12-05 2024-12-05 PlS Planned sale
Hopkinson Craig C.

EVP R&D, Chief Medical Officer

Officer
9,221 -13.4%
31.50
US$290,462 		9,221 -13.4% 31.50 US$290,462
2024-12-04 2024-12-04 PrS Proposed sale
Hopkinson Craig C.

Officer

Officer
14,349
30.77
US$441,550 		14,349 30.77 US$441,550
2024-12-04 2024-12-04 PlS Planned sale
Hopkinson Craig C.

EVP R&D, Chief Medical Officer

Officer
14,349 -17.2%
30.77
US$441,550 		14,349 -17.2% 30.77 US$441,550
2024-11-27 2024-11-27 PrS Proposed sale
Nichols Christian Todd

Officer

Officer
5,208
29.15
US$151,813 		5,208 29.15 US$151,813
2024-11-27 2024-11-27 PlS Planned sale
Nichols Christian Todd

SVP, Chief Commercial Officer

Officer
5,208 -7.9%
29.15
US$151,813 		5,208 -7.9% 29.15 US$151,813
2024-11-12 2024-11-11 PrS Proposed sale
Hopkinson Craig C.

Officer

Officer
58,996
30.08
US$1,774,578 		58,996 30.08 US$1,774,578
Explore more

More insider trading research around Alkermes Plc

More insider trades in IE
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity